Cel-Sci Corp. (CVM; 871006) (Seite 725)

    eröffnet am 30.10.03 18:31:27 von
    elcommandante

    neuester Beitrag 31.05.14 03:05:29 von
    binda
    Beiträge: 7.654
    ID: 791.230
    Aufrufe heute: 1
    Gesamt: 437.998


    Beitrag schreiben Ansicht: Normal
    Avatar
    ALF-FRED
    schrieb am 01.05.12 12:34:58
    Beitrag Nr. 7.241 (43.107.142)
    :eek: wenn es heute rappelt liegen alle besoffen unter dem Maibaum :laugh:

    http://seekingalpha.com/article/545051-cel-sci-corp-synergy-…
    Avatar
    Plaste
    schrieb am 03.05.12 08:31:14
    Beitrag Nr. 7.242 (43.113.738)
    ;)

    http://www.oep.com.tw/eng/business/MA-RA-Licensing.aspx


    Cancer Vaccines and Cancer Immunotherapy & Immunomodulation

    Tuesday, May 15, 2012 | 12:00 PM - 5:00 PM
    The New York Academy of Sciences

    http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438…

    unter Speakers oder Abstracts lesen


    Bin ja mal gespannt ob es am 15 Mai interessante News gibt. Ich denke das viele drauf spekulieren werden.
    Aus Erfahrung wissen wir ja, das dem nicht so sein sollte.

    mfg Plaste
    Avatar
    ALF-FRED
    schrieb am 07.05.12 00:26:45
    Beitrag Nr. 7.243 (43.128.059)
    http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438…


    unter sponsors :

    Academy Friends

    Bristol-Myers Squibb

    CEL-SCI Corporation
    Avatar
    ALF-FRED
    schrieb am 10.05.12 14:35:40
    Beitrag Nr. 7.244 (43.147.273)
    Avatar
    binda
    schrieb am 11.05.12 14:38:21
    Beitrag Nr. 7.245 (43.153.008)
    MarketWire · Mehr Nachrichten von MarketWire
    Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System / Five Star Equities Provides Stock Research on Cardium Therapeutics and CEL-SCI
    NEW YORK, NY -- (Marketwire) -- 05/11/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Cardium Therapeutics Inc. (NYSE Amex: CXM) and CEL-SCI Corporation (NYSE: CVM).

    Access to the full company reports can be found at:

    www.FiveStarEquities.com/CXM

    www.FiveStarEquities.com/CVM

    The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a press release: "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.

    Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

    Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. For the fourth quarter ended December 31, 2011, the Company presented a loss from operations of $1.9 million, compared to a $1.5 million loss from operations for the fourth quarter in 2010.

    CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine, currently being studied in a pivotal global Phase III clinical trial. The company reported that net loss available to shareholders for the quarter ended December 31, 2011 was $4,156,833 versus $6,250,952 during the same quarter a year prior.

    Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
    www.FiveStarEquities.com/disclaimer

    Add to Digg Bookmark with del.icio.us Add to Newsvine

    Contact:

    Five Star Equities

    Email Contact
    Avatar
    ALF-FRED
    schrieb am 14.05.12 06:15:26
    Beitrag Nr. 7.246 (43.159.901)
    Avatar
    schlumpftrader
    schrieb am 14.05.12 14:03:21
    Beitrag Nr. 7.247 (43.161.893)
    hallo,

    guckt euch mal bei www.nasdaq.com die pre-market quote von CEL-SCI an.

    was für eine augenweide!

    auch wenn am ende des heutigen tages nicht viel davon übrig bleiben sollte, so ist das zumindest jetzt einfach nur schöööön. :)

    bye
    schlumpftrader
    Avatar
    Plaste
    schrieb am 15.05.12 08:27:42
    Beitrag Nr. 7.248 (43.165.175)
    Avatar
    ALF-FRED
    schrieb am 15.05.12 16:19:21
    Beitrag Nr. 7.249 (43.167.967)
    CEL-SCI's Chief Scientific Officer Presents at Cancer Symposium



    CEL-SCI Corporation (NYSE MKT: CVM) announced that its Chief Scientific Officer, Eyal Talor, Ph.D., is making a presentation at 4:30 p.m. today in New York at the New York Academy of Sciences Symposium. This symposium will highlight current approaches in cancer immunotherapy and immunomodulation, and emerging cancer vaccines. The presentation is titled: "Multikine® Cancer Immunotherapy: Mechanism of Action, Clinical Experience, Phase III Global Study and Possible New Standard of Care".

    It is possible to sign up to listen to this presentation at: http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438c-9ff1-3bc8ca3ce4af.

    About CEL-SCI Corporation

    CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

    For more information, please visit www.cel-sci.com.

    Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval.Multikine has not been licensed or approvedfor sale, barter or exchangeby the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



    Contacts:

    CEL-SCI Corporation
    Gavin de Windt, 703-506-9460

    © 2012 Business Wire
    Avatar
    Umckaloabo
    schrieb am 16.05.12 11:47:45
    Beitrag Nr. 7.250 (43.172.076)
    Alles was ich bis jetzt gelesen habe ist wenig überzeugend.
    Ich habd das schon geahnt. Nur wage Dinge und immer im Konjunktiv gesprochen. Vorliegende Ergebnisee sehr differenziert. Das wird keine Kursbewegung nach sich ziehen. Wahrscheinlich müssen wir noch ein halbes Jahr warten. Wieder eine Enttäuschung.
    1 Antwort




    Beitrag zu dieser Diskussion schreiben

    Meistdiskutierte Aktien (24h)

    WertpapierBeiträge
    88
    78
    37
    37
    31
    25
    23
    20
    17
    17